Tessera Defense and Homeland Security (HLSQ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Oct, 2026Executive summary
Special meeting set for October 20, 2026; Proposal 1 would raise the 2026 Equity Incentive Plan reserve by 5,315,000 shares, from 685,000 to 6,000,000 post-split. The Board unanimously recommends FOR both proposals.
The Board adopted the amendment on September 24, 2026, subject to stockholder approval; if approved, it takes effect on the approval date.
Voting matters and shareholder proposals
Proposal 2 would authorize adjournment, if needed, to solicit more proxies; approval is not contingent on Proposal 1, and the Board recommends FOR.
Record holders as of October 5, 2026 may vote; 9,026,478 shares were outstanding, with one vote per share. Each proposal requires a majority of votes cast; abstentions and broker non-votes have no effect.
A majority of outstanding shares is required for a quorum; neither proposal is routine, so brokers cannot vote uninstructed shares.
Stockholder notices for 2027 annual-meeting proposals or nominations are due February 26–March 28, 2027; Rule 14a-19 notice for director nominees is due April 27, 2027.
Board of directors and corporate governance
Current directors are Reuven Yeganeh, Liat Bidas, Guy Arieli and Ran Shaked; Bidas, Arieli and Shaked qualify as independent, while Yeganeh does not due to his T3 Defense board service.
Bidas chairs the Audit and Nominating and Corporate Governance Committees; Arieli chairs Compensation. Arieli and Shaked serve on the Audit Committee, and Bidas and Shaked serve on Compensation.
Michael Oster became CEO in March 2026, David Rokach became CFO in February 2026, and Roy Timor-Rousso became Chief Business Officer in July 2026.
Latest events from Tessera Defense and Homeland Security
- Plan expansion vote would unlock CEO equity awards tied partly to EBITDA/share targets.HLSQ
Proxy filing - CEO and CFO awards hinge on Proposal 1 approval, with additional shares tied to future performance.HLSQ
Proxy filing - Vote sought to expand equity plan by 5.3M shares to support growth and retention.HLSQ
Proxy filing - First defense-tech revenue reported post-acquisitions, but liquidity and going concern risks persist.HLSQ
Q2 2026 - Proxy seeks approval for DFSL acquisition securities, reverse split, and auditor ratification.HLSQ
Proxy filing - Stockholders to vote on acquisition-related securities issuance, reverse split, and auditor change.HLSQ
Proxy filing - Shifted to defense/security tech, offering resale shares from acquisitions, with high dilution and financial risk.HLSQ
Registration filing - Merger, $50M financing, and clinical progress drive 2025 milestones amid ongoing losses and delisting risk.HLSQ
Q2 2024 - BX211 and BX004 show strong efficacy; $12M financing supports key clinical milestones.HLSQ
Q4 2024 & Study Result